Cyclic diarylheptanoids inhibit cell-mediated low-density lipoprotein oxidation

Area of Science:

• Phytochemistry
• Pharmacology
• Cardiovascular Research

Background:

• Atherosclerosis is a chronic inflammatory disease characterized by lipid accumulation in artery walls.
• Oxidation of low-density lipoprotein (LDL) is a key event in the pathogenesis of atherosclerosis.
• Natural products are a promising source of novel therapeutic agents for cardiovascular diseases.

Purpose of the Study:

• To isolate and characterize cyclic diarylheptanoids from Alnus japonica fruits.
• To evaluate the inhibitory effects of these compounds on LDL oxidation.
• To assess the potential anti-atherogenic activity of these compounds.

Main Methods:

• Extraction and isolation of compounds from Alnus japonica fruit methanol extract.
• Chemical characterization of isolated compounds using spectroscopic methods.
• Assessment of LDL oxidation inhibition using the thiobarbituric acid-reactive substance (TBARS) assay.
• Evaluation of cell-mediated LDL oxidation.
• In vivo anti-atherogenesis study in low-density lipoprotein receptor-deficient mice.

Main Results:

• Two cyclic diarylheptanoids, garugamblin-3 (1) and acerogenin L (2), were isolated.
• Both compounds significantly inhibited LDL oxidation in vitro, with IC50 values of 2.9 microM (1) and 1.7 microM (2).
• Compounds 1 and 2 demonstrated over five-fold greater inhibition of cell-mediated LDL oxidation compared to probucol at 10 microM.
• Compound 1 did not show anti-atherogenic effects in vivo in LDL receptor-deficient mice.

Conclusions:

• Garugamblin-3 and acerogenin L possess potent LDL oxidation inhibitory properties.
• These compounds represent potential therapeutic leads for preventing or treating atherosclerosis.
• Further investigation is warranted to elucidate the in vivo mechanisms and efficacy of these natural compounds.